PAVmed (PAVM) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 09, 2023
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-37685
Entity Registrant Name	PAVMED INC.
Entity Central Index Key	0001624326
Entity Tax Identification Number	47-1214177
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	360 Madison Avenue
Entity Address, Address Line Two	25th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	(917)
Local Phone Number	813-1828
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		120,759,886
Common Stock, $0.001 Par Value Per Share [Member]
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	PAVM
Security Exchange Name	NASDAQ
Series Z Warrants, Each To Purchase One Share Of Common Stock [Member]
Title of 12(b) Security	Series Z Warrants, each to purchase one share of Common Stock
Trading Symbol	PAVMZ
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 26,408	$ 39,744
Accounts receivable	36	17
Prepaid expenses, deposits, and other current assets	6,017	4,165
Total current assets	32,461	43,926
Fixed assets, net	1,820	2,451
Operating lease right-of-use assets	4,663	3,037
Intangible assets, net	1,929	3,445
Other assets	1,147	1,121
Total assets	42,020	53,980
Current liabilities:
Accounts payable	2,165	2,704
Accrued expenses and other current liabilities	5,485	3,705
Operating lease liabilities, current portion	1,574	1,141
Senior Secured Convertible Notes - at fair value	44,990	33,650
Derivative liability - at fair value	291
Total current liabilities	54,505	41,200
Operating lease liabilities, less current portion	3,343	1,846
Total liabilities	57,848	43,046
Commitments and contingencies (Note 9)
Stockholders’ Equity:
Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,279,601 at September 30, 2023 and 1,205,759 shares at December 31, 2022	2,916	2,695
Common stock, $0.001 par value. Authorized, 250,000,000 shares; 119,701,959 and 94,510,537 shares outstanding as of September 30, 2023 and December 31, 2022, respectively	120	95
Additional paid-in capital	232,234	216,106
Accumulated deficit	(278,529)	(228,169)
Treasury stock		(408)
Total PAVmed Inc. Stockholders’ Equity (Deficit)	(43,259)	(9,681)
Noncontrolling interests	27,431	20,615
Total Stockholders’ Equity (Deficit)	(15,828)	10,934
Total Liabilities and Stockholders’ Equity (Deficit)	$ 42,020	$ 53,980

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares outstanding	119,701,959	94,510,537
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	1,279,601	1,205,759
Preferred stock, shares outstanding	1,279,601	1,205,759

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 791	$ 76	$ 1,403	$ 265
Operating expenses:
Cost of revenue	1,779	1,626	4,809	1,996
Sales and marketing	4,016	4,736	12,893	13,559
General and administrative	6,858	10,374	23,916	31,254
Amortization of acquired intangible assets	505	505	1,516	1,278
Research and development	3,161	6,202	10,681	18,664
Total operating expenses	16,319	23,443	53,815	66,751
Operating loss	(15,528)	(23,367)	(52,412)	(66,486)
Other income (expense):
Interest income	124	54	408	63
Interest expense	(159)	(525)	(570)	(1,049)
Change in fair value - Senior Secured Convertible Notes	(4,392)	261	(5,772)	(1,739)
Loss on issue and offering costs - Senior Secured Convertible Note		(1,232)	(1,186)	(4,332)
Debt extinguishments loss - Senior Secured Convertible Notes	(1,764)	(5,123)	(3,032)	(5,123)
Change in fair value - derivative liability	(31)		(291)
Gain on sale of intellectual property			1,000
Other income (expense), net	(6,222)	(6,565)	(9,443)	(12,180)
Loss before provision for income tax	(21,750)	(29,932)	(61,855)	(78,666)
Provision for income taxes
Net loss before noncontrolling interests	(21,750)	(29,932)	(61,855)	(78,666)
Net loss attributable to the noncontrolling interests	4,079	3,806	11,716	10,143
Net loss attributable to PAVmed Inc.	(17,671)	(26,126)	(50,139)	(68,523)
Less: Series B Convertible Preferred Stock dividends earned	(77)	(71)	(226)	(209)
Net loss attributable to PAVmed Inc. common stockholders	$ (17,748)	$ (26,197)	$ (50,365)	$ (68,732)
Per share information:
Net loss per share attributable to PAVmed Inc. - basic	$ (0.16)	$ (0.29)	$ (0.48)	$ (0.78)
Net loss per share attributable to PAVmed Inc. - diluted	(0.16)	(0.29)	(0.48)	(0.78)
Net loss per share attributable to PAVmed Inc. common stockholders - basic	(0.16)	(0.29)	(0.48)	(0.78)
Net loss per share attributable to PAVmed Inc. common stockholders - diluted	$ (0.16)	$ (0.29)	$ (0.48)	$ (0.78)
Weighted average common shares outstanding, basic	111,941,269	89,758,927	104,516,464	87,724,124
Weighted average common shares outstanding, diluted	111,941,269	89,758,927	104,516,464	87,724,124

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Noncontrolling Interest [Member]	Total
Beginning balance at Dec. 31, 2021	$ 2,419	$ 86	$ 198,071	$ (138,910)		$ 17,752	$ 79,418
Beginning balance, shares at Dec. 31, 2021	1,113,919	86,367,845
Ending balance at Jun. 30, 2022	$ 2,554	$ 87	201,327	(181,442)	(548)	19,426	41,404
Ending balance, shares at Jun. 30, 2022	1,158,950	87,023,211
Beginning balance at Dec. 31, 2021	$ 2,419	$ 86	198,071	(138,910)		17,752	79,418
Beginning balance, shares at Dec. 31, 2021	1,113,919	86,367,845
Dividends declared - Series B Convertible Preferred Stock	$ 205			(205)
Dividends declared - Series B Convertible Preferred Stock, shares	68,227
Conversions - Senior Secured Convertible Note		$ 5	10,107				10,112
Conversions - Senior Secured Convertible Note, shares		5,013,908
Purchase - Employee Stock Purchase Plan			218		140		358
Purchase - Employee Stock Purchase Plan, shares		194,240
Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan						109	109
Impact of subsidiary equity transactions			1,375			(1,375)
Stock-based compensation - PAVmed Inc.			4,206				4,206
Stock-based compensation - majority-owned subsidiaries						10,377	10,377
Net Loss				(68,523)		(10,143)	(78,666)
Vest - restricted stock awards			(1)				(1)
Vest - restricted stock awards, shares		541,666
Issuance - majority-owned subsidiary common stock - Settlement APA-RDx - Installment Payment						427	427
Treasury stock					(548)		(548)
Treasury stock, shares		(188,846)
Conversions - Series B Convertible Preferred Stock
Conversions - Series B Convertible Preferred Stock, shares	(45,000)	45,000
Exercise - stock options of majority-owned subsidiary						694	694
Issuance - majority-owned subsidiary common stock - Committed Equity Facility, net of financing charges						1,767	1,767
Exercise - Series Z warrants
Exercise - Series Z warrants, shares		5
Exercise - stock options		$ 1	302				303
Exercise - stock options, shares		299,999
Ending balance at Sep. 30, 2022	$ 2,624	$ 92	214,278	(207,638)	(408)	19,608	28,556
Ending balance, shares at Sep. 30, 2022	1,182,101	92,228,862
Beginning balance at Jun. 30, 2022	$ 2,554	$ 87	201,327	(181,442)	(548)	19,426	41,404
Beginning balance, shares at Jun. 30, 2022	1,158,950	87,023,211
Dividends declared - Series B Convertible Preferred Stock	$ 70			(70)
Dividends declared - Series B Convertible Preferred Stock, shares	23,196
Conversions - Senior Secured Convertible Note		$ 5	10,107				10,112
Conversions - Senior Secured Convertible Note, shares		5,013,908
Purchase - Employee Stock Purchase Plan					140		140
Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan						109	109
Impact of subsidiary equity transactions			1,363			(1,363)
Stock-based compensation - PAVmed Inc.			1,481				1,481
Stock-based compensation - majority-owned subsidiaries						3,283	3,283
Net Loss				(26,126)		(3,806)	(29,932)
Issuance - majority-owned subsidiary common stock - Settlement APA-RDx - Installment Payment						186	186
Treasury stock
Treasury stock, shares		191,698
Conversions - Series B Convertible Preferred Stock
Conversions - Series B Convertible Preferred Stock, shares	(45,000)	45,000
Exercise - stock options of majority-owned subsidiary						6	6
Issuance - majority-owned subsidiary common stock - Committed Equity Facility, net of financing charges						1,767	1,767
Ending balance at Sep. 30, 2022	$ 2,624	$ 92	214,278	(207,638)	(408)	19,608	28,556
Ending balance, shares at Sep. 30, 2022	1,182,101	92,228,862
Ending balance at Dec. 31, 2022	$ 2,695	$ 95	216,106	(228,169)	(408)	20,615	10,934
Ending balance, shares at Dec. 31, 2022	1,205,759	94,510,537
Ending balance at Jun. 30, 2023	$ 2,841	$ 109	226,321	(260,783)		30,682	(830)
Ending balance, shares at Jun. 30, 2023	1,254,497	108,537,994
Beginning balance at Dec. 31, 2022	$ 2,695	$ 95	216,106	(228,169)	(408)	20,615	10,934
Beginning balance, shares at Dec. 31, 2022	1,205,759	94,510,537
Dividends declared - Series B Convertible Preferred Stock	$ 221			(221)
Dividends declared - Series B Convertible Preferred Stock, shares	73,842
Conversions - Senior Secured Convertible Note		$ 20	8,388				8,408
Conversions - Senior Secured Convertible Note, shares		20,383,445
Conversions - majority-owned subsidiary common stock - Senior Secured Convertible Note						167	167
Purchase - Employee Stock Purchase Plan		$ 1	198		60		259
Purchase - Employee Stock Purchase Plan, shares		688,384
Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan						551	551
Impact of subsidiary equity transactions			1,984			(1,984)
Stock-based compensation - PAVmed Inc.			3,266				3,266
Stock-based compensation - majority-owned subsidiaries			876			5,029	5,905
Net Loss				(50,139)		(11,716)	(61,855)
Issue common stock - PAVM ATM Facility		$ 2	1,164				1,166
Issue common stock - PAVM ATM Facility, shares		2,330,747
Vest - restricted stock awards
Vest - restricted stock awards, shares		100,000
Issuance - majority-owned subsidiary common stock - At-The-Market Facility, net of financing charges						284	284
Issuance - majority-owned subsidiary common stock - Settlement APA-RDx - Installment Payment						713	713
Issuance - vendor service agreement		$ 2	600			147	749
Issuance - vendor service agreement, shares		1,500,000
Issuance - majority-owned subsidiary preferred stock						13,625	13,625
Treasury stock			(348)		348
Treasury stock, shares		188,846
Ending balance at Sep. 30, 2023	$ 2,916	$ 120	232,234	(278,529)		27,431	(15,828)
Ending balance, shares at Sep. 30, 2023	1,279,601	119,701,959
Beginning balance at Jun. 30, 2023	$ 2,841	$ 109	226,321	(260,783)		30,682	(830)
Beginning balance, shares at Jun. 30, 2023	1,254,497	108,537,994
Dividends declared - Series B Convertible Preferred Stock	$ 75			(75)
Dividends declared - Series B Convertible Preferred Stock, shares	25,104
Conversions - Senior Secured Convertible Note		$ 10	3,978				3,988
Conversions - Senior Secured Convertible Note, shares		10,859,964
Conversions - majority-owned subsidiary common stock - Senior Secured Convertible Note						167	167
Purchase - Employee Stock Purchase Plan		$ 1	76				77
Purchase - Employee Stock Purchase Plan, shares		304,001
Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan						275	275
Impact of subsidiary equity transactions			651			(651)
Stock-based compensation - PAVmed Inc.			978				978
Stock-based compensation - majority-owned subsidiaries			230			1,037	1,267
Net Loss				(17,671)		(4,079)	(21,750)
Ending balance at Sep. 30, 2023	$ 2,916	$ 120	$ 232,234	$ (278,529)		$ 27,431	$ (15,828)
Ending balance, shares at Sep. 30, 2023	1,279,601	119,701,959

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net loss - before noncontrolling interest (“NCI”)	$ (61,855)	$ (78,666)
Adjustments to reconcile net loss - before NCI to net cash used in operating activities
Depreciation and amortization expense	2,207	1,731
Stock-based compensation	9,171	14,583
Gain on sale of intellectual property	(1,000)
APA-RDx: Issue common stock of majority-owned subsidiary - settle termination payment	713	427
Issue common stock - vendor service agreement	625
Change in fair value - Senior Secured Convertible Notes	5,772	1,739
Loss on issue - Senior Secured Convertible Note	1,111	3,523
Debt extinguishment loss - Senior Secured Convertible Note	3,032	5,123
Change in fair value - derivative liability	291
Non-cash lease expense	304	82
Changes in operating assets and liabilities:
Accounts receivable	(18)	169
Prepaid expenses, deposits and current and other assets	(1,757)	(563)
Accounts payable	(538)	(981)
Accrued expenses and other current liabilities	1,780	(1,329)
Net cash flows used in operating activities	(40,162)	(54,162)
Cash flows from investing activities
Purchase of equipment	(59)	(1,242)
Proceeds from sale of intellectual property	1,000
Asset acquisitions		(3,200)
Net cash flows used in investing activities	941	(4,442)
Cash flows from financing activities
Proceeds – issue of preferred stock - majority-owned subsidiary	13,625
Proceeds – issue of Senior Secured Convertible Note	10,000	35,227
Proceeds – issue of common stock - At-The-Market Facility	1,166
Proceeds – majority-owned subsidiary common stock - Committed Equity Facility and At-The-Market Facility	284	1,807
Proceeds – exercise of stock options		302
Proceeds – issue common stock – Employee Stock Purchase Plan	259	358
Proceeds – majority-owned subsidiary common stock – Employee Stock Purchase Plan	551	109
Proceeds – exercise of stock options issued under equity plan of majority owned subsidiary		694
Purchase Treasury Stock – payment of employee payroll tax obligation in connection with stock-based compensation		(366)
Net cash flows provided by financing activities	25,885	38,131
Net increase (decrease) in cash	(13,336)	(20,473)
Cash, beginning of period	39,744	77,258
Cash, end of period	$ 26,408	$ 56,785

The Company

The Company	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1 — The Company Description of the Business PAVmed Inc. and Subsidiaries, referred to herein as “PAVmed” or the “Company,” is comprised of PAVmed Inc. and its wholly-owned subsidiary and its majority-owned subsidiaries, inclusive of Lucid Diagnostics Inc. (“Lucid Diagnostics” or “Lucid”) and Veris Health Inc. (“Veris Health” or “Veris”). PAVmed is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, including through Lucid Diagnostics, a commercial-stage cancer prevention diagnostics company, and Veris Health, a private digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. The Company’s current central focus is on the commercialization of Lucid’s EsoGuard assay and Veris Health’s Veris Cancer Care Platform. As resources permit, we will continue to explore internal and external innovations that fulfill our project selection criteria without limiting ourselves to any target specialty or condition. Liquidity The Company has financed its operations principally through public and private issuances of its common stock, preferred stock, common stock purchase warrants, and debt. The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing research and development activities and conducting clinical trials. The Company expects to continue to experience recurring losses from operations and will continue to fund its operations with debt and equity financing transactions, including current obligations on the Company’s existing convertible debt which in accordance with management’s plans may include conversions to equity and refinancing our existing debt obligations to extend maturity dates. Notwithstanding, however, with the cash on-hand as of the date hereof and other debt and equity committed sources of financing, conversion and refinancing of existing convertible notes, the Company expects to be able to fund its operations for one year from the date of the issue of the Company’s consolidated financial statements included herein in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Significant Accounting Policies The Company’s significant accounting policies are as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on March 14, 2023, except as otherwise noted herein below. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of PAVmed and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), and include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority-ownership interest and has controlling financial interest in each of: Lucid Diagnostics and Veris Health, with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity (deficit), including the recognition in the unaudited condensed consolidated statement of operations of a net loss attributable to the noncontrolling interest based on the respective minority-interest equity ownership of each majority-owned subsidiary. See Note 15, Noncontrolling Interest As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2022 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Company’s unaudited condensed consolidated financial information. The consolidated results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2023 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Company’s audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K as filed with the SEC on March 14, 2023. All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts. Note 2 — Summary of Significant Accounting Policies Use of Estimates In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Revenue Recognition Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient’s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The key aspects considered by the Company include the following: Contracts Performance obligations Transaction price If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience. Allocate transaction price Practical Expedients Note 2 — Summary of Significant Accounting Policies Fair Value Option (“FVO”) Election Under a Securities Purchase Agreement dated March 31, 2022, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the “April 2022 Senior Convertible Note”, and a Senior Secured Convertible Note dated September 8, 2022, referred to herein as the “September 2022 Senior Convertible Note”, which are accounted under the “fair value option election” as discussed below. Under a Securities Purchase Agreement dated March 13, 2023, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the “Lucid March 2023 Senior Convertible Note”, which is accounted under the “fair value option election” as discussed below. Under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivative and Hedging Alternatively, FASB ASC Topic 825, Financial Instruments See Note 10, Financial Instruments Fair Value Measurements Debt Reclassifications Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the unaudited condensed consolidated financial statements and accompanying notes to the unaudited condensed consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The updated guidance requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets, including trade receivables. The guidance was adopted by the Company on January 1, 2023. The adoption of the ASU did not have an impact on the Company’s unaudited condensed consolidated financial statements.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Note 3 — Revenue from Contracts with Customers EsoGuard Commercialization Agreement The Company, through its majority-owned subsidiary, Lucid Diagnostics, entered into the EsoGuard Commercialization Agreement, dated August 1, 2021, with its former commercial laboratory service provider, ResearchDx Inc. (“RDx”), an unrelated third-party. The EsoGuard Commercialization Agreement was on a month-to-month basis, and was terminated on February 25, 2022 upon the execution of an asset purchase agreement (“APA”) dated February 25, 2022, between LucidDx Labs Inc. (a wholly-owned subsidiary of Lucid Diagnostics) and RDx, with such agreement further discussed in Note 5 , Asset Purchase Agreement and Management Services Agreement. Note 3 — Revenue from Contracts with Customers Revenue Recognized In the three and nine months ended September 30, 2023, the Company recognized total revenue of $ 791 1,403 76 265 100 Cost of Revenue The cost of revenues principally includes the costs related to the Company’s laboratory operations (excluding estimated costs associated with research activities), the costs related to the EsoCheck cell collection device, cell sample mailing kits and license royalties. In the three and nine months ended September 30, 2023, the cost of revenue was $ 1,779 4,809 1,626 1,996

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 — Related Party Transactions Case Western Reserve University and Physician Inventors - Amended CWRU License Agreement Case Western Reserve University (“CWRU”) and each of the three physician inventors (“Physician Inventors”) of the intellectual property licensed under the amended and restated patent license agreement with CWRU, dated August 23, 2021 (the “Amended CWRU License Agreement”), each hold a minority equity ownership interest in Lucid Diagnostics Inc. The expenses incurred with respect to the Amended CWRU License Agreement and the three Physician Inventors, as classified in the accompanying unaudited condensed consolidated statement of operations for the periods indicated are summarized as follows: Schedule of Incurred Expenses of Minority Shareholders 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of Revenue CWRU – Royalty Fees $ 42 $ 4 $ 76 $ 13 Cost of revenue $ 42 $ 4 $ 76 $ 13 General and Administrative Expense Amended CWRU – License Agreement - reimbursement of patent legal fees 343 — 732 209 Stock-based compensation expense – Physician Inventors’ restricted stock awards — 275 180 819 Research and Development Expense Fees - Physician Inventors’ consulting agreements 5 15 15 32 Sponsored research agreement — 4 — 6 Stock-based compensation expense – Physician Inventors’ stock options 52 52 157 151 Total Related Party Expenses $ 442 $ 350 $ 1,160 $ 1,230 As of September 30, 2023, Lucid had an outstanding payable of $ 820 Note 4 — Related Party Transactions - See Note 12, Stock-Based Compensation Noncontrolling Interest Other Related Party Transactions Effective June 2021, Veris Health entered into a consulting agreement with Andrew Thoreson, M.D. which provides for compensation on a contractual rate per hour for consulting services provided. Dr. Thoreson holds a partial ownership interest in the legal entity which holds a minority interest in Veris Health. Veris Health recognized general and administrative expense of $ 0 25 8 45

Asset Purchase Agreement and Ma

Asset Purchase Agreement and Management Services Agreement	9 Months Ended
	Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Asset Purchase Agreement and Management Services Agreement	Note 5 — Asset Purchase Agreement and Management Services Agreement Asset Purchase Agreement and Management Services Agreement - ResearchDx Inc. LucidDx Labs, a wholly-owned subsidiary of Lucid Diagnostics, entered into an asset purchase agreement (“APA”) dated February 25, 2022, with ResearchDx, Inc. (“RDx”), an unrelated third-party (“APA-RDx”). Under the APA-RDx, LucidDx Labs acquired certain assets from RDx which were combined with LucidDx Labs purchased and leased property and equipment to establish a Company-owned Commercial Lab Improvements Act (“CLIA”) certified, College of American Pathologists (“CAP”) accredited commercial clinical laboratory capable of performing the EsoGuard® Esophageal DNA assay, inclusive of DNA extraction, next generation sequencing (“NGS”) and specimen storage. Prior to February 25, 2022, RDx provided such laboratory services at its owned CLIA-certified, CAP-accredited clinical laboratory. In connection with the execution and delivery of the APA-RDx, LucidDx Labs and RDx entered into a separate management services agreement (“MSA-RDx”), dated and effective February 25, 2022, pursuant to which RDx provided certain testing and related services for the Laboratory. The total purchase price consideration payable under the APA-RDx is a face value of $ 3,200 3,200 Intangible Assets, net. Termination of Management Services Agreement and Modification of Other Payment Obligations - ResearchDx Inc On February 14, 2023, Lucid Diagnostics and LucidDx Labs entered into an agreement (the “MSA Termination Agreement”) with RDx, pursuant to which the parties mutually agreed to terminate the MSA-RDx without cause. The termination was effective as February 10, 2023. Until the termination of the management service agreement with RDx, RDx had continued to provide certain testing and related services for the Laboratory in accordance with the terms of the MSA-RDx. The MSA Termination Agreement reduces the remaining amounts of the earnout payments and management fees due under the APA-RDx and the MSA-RDx to $ 713 553,436

Prepaid Expenses, Deposits, and

Prepaid Expenses, Deposits, and Other Current Assets	9 Months Ended
	Sep. 30, 2023
Prepaid Expenses Deposits And Other Current Assets
Prepaid Expenses, Deposits, and Other Current Assets	Note 6 — Prepaid Expenses, Deposits, and Other Current Assets Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current Assets September 30, 2023 December 31, 2022 Advanced payments to service providers and suppliers $ 432 $ 599 Prepaid insurance 479 300 Deposits 4,581 3,005 EsoCheck cell collection supplies 190 59 EsoGuard mailer supplies — 52 Veris Box supplies 335 150 Total prepaid expenses, deposits and other current assets $ 6,017 $ 4,165

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases
Leases	Note 7 — Leases During the nine months ended September 30, 2023, the Company entered into additional lease agreements that have commenced and are classified as operating leases and short-term leases, including for each of: principal corporate offices and additional Lucid Test Centers. The Company’s future lease payments as of September 30, 2023, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company’s unaudited condensed consolidated balance sheets are as follows: Schedule of Future Lease Payments 2023 (remainder of year) $ 485 2024 1,852 2025 835 2026 787 2027 617 Thereafter 1,319 Total lease payments $ 5,895 Less: imputed interest (978 ) Present value of lease liabilities $ 4,917 Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows: Schedule of Supplemental Cash Flow Information Related to Cash and Non-cash Activities with Leases 2023 2022 Nine Months Ended September 30, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,080 $ 763 Non-cash investing and financing activities Right-of-use assets obtained in exchange for new operating lease liabilities $ 2,728 $ 3,753 Weighted-average remaining lease term - operating leases (in years) 4.68 3.08 Weighted-average discount rate - operating leases 7.875 % 7.875 % As of September 30, 2023 and December 31, 2022, the Company’s right-of-use assets from operating leases were $ 4,663 3,037 4,917 2,987 1,574 1,141 3,343 1,846 In September 2022, the Company entered into a lease agreement for its principal corporate offices, in New York, New York. The lease agreement term is from the September 15, 2022 execution date to the date which is seven years and eight months from the lease commencement date, with the rent abated for the first eight months of the lease term 3.2

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Note 8 — Intangible Assets, net Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets, Less Accumulated Amortization Estimated Useful Life September 30, 2023 December 31, 2022 Defensive asset 60 $ 2,105 $ 2,105 Laboratory licenses and certifications and laboratory information management software 24 3,200 3,200 Other 1 year 70 70 Total Intangible assets 5,375 5,375 Less Accumulated Amortization (3,446 ) (1,930 ) Intangible Assets, net $ 1,929 $ 3,445 The defensive technology intangible asset was recognized upon its acquisition of CapNostics, an unrelated third-party, for total purchase consideration paid on the October 5, 2021 acquisition date of approximately $ 2.1 60 The intangible assets recognized under the APA-RDx are the laboratory licenses and certifications, inclusive of a CLIA certification, CAP accreditation, and clinical laboratory licenses for five (5) U.S. States transfer to the Company from RDx, and a laboratory information management software perpetual-use royalty-free license granted under the APA-RDx, with such intangible asset having a useful life of twenty-four months commencing on the APA-RDx February 25, 2022 transaction date. Amortization expense of the intangible assets discussed above was $ 505 505 1,516 1,278 Schedule of Estimated Amortization Expense for Intangible Assets 2023 (remainder of year) $ 505 2024 688 2025 421 2026 315 Total $ 1,929

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitment and Contingencies	Note 9 — Commitment and Contingencies Other Matters In the ordinary course of PAVmed business, particularly as it begins commercialization of its products, the Company may be subject to certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. The Company is not aware of any such pending legal or other proceedings that are reasonably likely to have a material impact on the Company. Notwithstanding, legal proceedings are subject-to inherent uncertainties, and an unfavorable outcome could include monetary damages, and excessive verdicts can result from litigation, and as such, could result in a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows. Additionally, although the Company has specific insurance for certain potential risks, the Company may in the future incur judgments or enter into settlements of claims which may have a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows.

Financial Instruments Fair Valu

Financial Instruments Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Financial Instruments Fair Value Measurements	Note 10 — Financial Instruments Fair Value Measurements Recurring Fair Value Measurements The fair value hierarchy table for the periods indicated is as follows: Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis Fair Value Measurement on a Recurring Basis at Reporting Date Using 1 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total September 30, 2023 Senior Secured Convertible Note - April 2022 $ — $ — $ 19,400 $ 19,400 Senior Secured Convertible Note - September 2022 — — 11,100 11,100 Lucid Senior Secured Convertible Note - March 2023 — — 14,490 14,490 Derivative liability — — 291 291 Totals $ — $ — $ 45,281 $ 45,281 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total December 31, 2022 Senior Secured Convertible Note - April 2022 $ — $ — $ 22,000 $ 22,000 Senior Secured Convertible Note - September 2022 — — 11,650 11,650 Totals $ — $ — $ 33,650 $ 33,650 1 There were no transfers between the respective Levels during the period ended September 30, 2023. As discussed in Note 11, Debt 27.5 11.25 As discussed in Note 11, Debt, 11.1 The estimated fair value of the financial instruments classified within the Level 3 category was determined using both observable inputs and unobservable inputs. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs. The estimated fair value of the Lucid March 2023 Senior Convertible Note as of each of March 21, 2023 and September 30, 2023, and the estimated fair value of the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note as of September 30, 2023, were computed using a Monte Carlo simulation of the present value of its cash flows using a synthetic credit rating analysis and a required rate-of-return, using the following assumptions: Schedule of Fair Value Assumption Used April 2022 Senior Convertible Note: September 2022 Senior Convertible Note: Lucid March 2023 Senior Convertible Note: Lucid March 2023 Senior Convertible Note: Fair Value $ 19,400 $ 11,100 $ 11,900 $ 14,490 Face value principal payable $ 17,602 $ 10,043 $ 11,111 $ 11,019 Required rate of return 11.350 % 11.300 % 11.00 % 11.10 % Conversion Price $ 5.00 $ 5.00 $ 5.00 $ 5.00 Value of common stock $ 0.30 $ 0.30 $ 1.54 $ 1.17 Expected term (years) 0.51 0.94 2.00 1.47 Volatility 240.00 % 240.00 % 75.00 % 65.00 % Risk free rate 5.40 % 5.32 % 4.09 % 5.13 % Dividend yield — % — % — % — % Note 10 — Financial Instruments Fair Value Measurements Derivative Liability - Written Protective Put The Company, through its majority-owned subsidiary Veris Health, entered into a Research and Development Agreement, with an effective date of May 31, 2023, with an unrelated third-party technical services provider (the “May 31, 2023 R&D Agreement”). The principal service to be provided by the service provider under the May 31, 2023 R&D Agreement was the continued development of the electronics and firmware for the Veris Health implantable physiologic monitor. As discussed in Note 14, Common Stock and Common Stock Purchase Warrants 1.5 750 The resolution of the contingent settlement-in-full with respect to the issued shares of common stock of the Company is predicated on and subject-to such issued shares having a $ 750 If the fair market value, as such amount is computed as described above, is equal-to or greater than $750, then no further contractual consideration is required. However, if such fair market value is less than $ 750 750 The contingent additional contractual consideration obligation is deemed to be a separate unit-of-account, in the form of a written protective put, and recognized as a derivative liability measured at estimated fair value. The derivative liability had an initial May 31, 2023 estimated fair value of approximately $ 262 291 The estimated fair value of the written protective put derivative liability, as such is discussed above, were computed using a Monte Carlo simulation to generate stock price paths (assuming geometric-Brownian motion) of the PAVmed Inc. common stock to compute the respective written protective put expected fair value, with the principal assumptions of such estimated fair value computation, for the respective measurement dates noted, as follows: Schedule of Fair Value Assumption Used As of: As of: Fair Value $ 262 $ 291 Contractual minimum effective conversion price $ 0.50 $ 0.50 Price per share $ 0.40 $ 0.30 Remaining expected term (years) 0.50 0.17 Volatility 160.00 % 240.00 % Risk free rate 5.30 % 5.40 % Dividend yield — % — % The estimated fair values recognized with respect to the senior secured convertible debt and the written protective put derivative liability, as each is discussed above, utilized PAVmed and Lucid Diagnostics common stock prices, along with certain Level 3 inputs (as presented in the respective tables above), in the development of Monte Carlo simulation models, discounted cash flow analyses, and /or Black-Scholes valuation models. The estimated fair values are subjective and are affected by changes in inputs to the valuation models and analyses, including the respective common stock prices, the dividend yields, the risk-free rates based on U.S. Treasury security yields, and certain other Level-3 inputs including, assumptions regarding the estimated volatility in the value of the respective common stock prices. Changes in these assumptions can materially affect the recognized estimated fair values.

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	Note 11 — Debt The fair value and face value principal outstanding of the Senior Convertible Notes as of the dates indicated are as follows: Summary of Outstanding Debt Contractual Maturity Date Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value April 2022 Senior Convertible Note April 4, 2024 7.875 % $ 5.00 $ 17,602 $ 19,400 September 2022 Senior Convertible Note September 6, 2024 7.875 % $ 5.00 $ 10,043 $ 11,100 Lucid March 2023 Senior Convertible Note March 21, 2025 7.875 % $ 5.00 $ 11,019 $ 14,490 Balance as of September 30, 2023 $ 38,664 $ 44,990 Contractual Maturity Date Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value April 2022 Senior Convertible Note April 4, 2024 7.875 % $ 5.00 $ 21,497 $ 22,000 September 2022 Senior Convertible Note September 6, 2024 7.875 % $ 5.00 $ 11,250 $ 11,650 Balance as of December 31, 2022 $ 32,747 $ 33,650 The changes in the fair value of debt during the three and nine months ended September 30, 2023 is as follows: Schedule of Changes in Fair Value of Debt April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - June 30, 2023 $ 19,530 $ 11,850 $ 11,610 $ 42,990 $ — Face value principal – issue date Fair value adjustment – issue date Installment repayments – common stock (952 ) (1,207 ) (92 ) (2,251 ) — Non-installment payments – common stock (41 ) (51 ) (49 ) (141 ) — Change in fair value 863 508 3,021 4,392 (4,392 ) Fair Value at September 30, 2023 $ 19,400 $ 11,100 $ 14,490 $ 44,990 - Other Income (Expense) - Change in fair value – three months ended September 30, 2023 $ (4,392 ) April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - December 31, 2022 $ 22,000 $ 11,650 $ — $ 33,650 $ — Fair Value, Beginning $ 22,000 $ 11,650 $ — $ 33,650 $ — Face value principal – issue date — — 11,111 11,111 — Fair value adjustment – issue date — — 789 789 (789 ) Installment repayments – common stock (3,895 ) (1,207 ) (92 ) (5,194 ) — Non-installment payments – common stock (249 ) (51 ) (49 ) (349 ) — Change in fair value 1,544 708 2,731 4,983 (4,983 ) Fair Value at September 30, 2023 $ 19,400 $ 11,100 $ 14,490 $ 44,990 Fair Value, Ending $ 19,400 $ 11,100 $ 14,490 $ 44,990 Other Income (Expense) - Change in fair value – nine months ended September 30, 2023 $ (5,772 ) Note 11 — Debt PAVmed - Senior Secured Convertible Notes The Company entered into a Securities Purchase Agreement (“SPA”) dated March 31, 2022, with an accredited institutional investor (“Investor”, “Lender”, and /or “Holder”), wherein, the Company agreed to sell, and the Investor agreed to purchase an aggregate of $ 50.0 27.5 22.5 Under the SPA, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the “April 2022 Senior Convertible Note”, with such note having a $ 27.5 7.875 5.00 April 4, 2024 Under the same SPA, the Company issued an additional Senior Secured Convertible Note dated September 8, 2022, referred to herein as the “September 2022 Senior Convertible Note”, with such note having a $ 11.25 7.875 5.00 September 6, 2024 The Company is subject to financial covenants requiring: (i) a minimum of $8.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Company’s average market capitalization over the prior ten trading days, to not exceed 30% (the “Debt to Market Cap Ratio Test”); and (iii) the Company’s market capitalization to at no time be less than $75 million In the nine months ended September 30, 2023, approximately $ 5,102 of principal repayments along with approximately $ 300 of interest expense thereon, were settled through the issuance of 20,383,445 shares of common stock of the Company, with such shares having a fair value of approximately $ 8,408 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). The conversions resulted in a debt extinguishment loss of $ 1,738 and $ 3,006 in the three and nine months ended September 30, 2023. Lucid Diagnostics - Senior Secured Convertible Note Lucid Diagnostics entered into a Securities Purchase Agreement (“Lucid SPA”) dated March 13, 2023, with an accredited institutional investor (“Investor”, “Lender”, and /or “Holder”), wherein, Lucid agreed to sell, and the Investor agreed to purchase an aggregate of $ 11.1 Under the SPA dated March 13, 2023, Lucid issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the “Lucid March 2023 Senior Convertible Note”, with such note having a $ 11.1 7.875 5.00 March 21, 2025 The Lucid March 2023 Senior Convertible Note proceeds were $ 9.925 1.186 During the period from March 21, 2023 to September 20, 2023, Lucid is required to pay interest expense only (on the $ 11.1 7.875 148 391 Commencing September 21, 2023, and then on each of the successive first and tenth trading day of each month thereafter through to and including March 14, 2025 (each referred to as an “Installment Date”); and on the March 21, 2025 292 Note 11 — Debt In addition to the Installment Amount repayments, the Holder may elect to accelerate the conversion of future Installment Amount repayments, and interest thereon, subject to certain restrictions, as defined, utilizing the then current conversion price of the most recent Installment Date conversion price. The payment of all amounts due and payable under this senior convertible note is guaranteed by Lucid’s subsidiaries; and the obligations under this senior convertible note are secured by all of the assets of Lucid and its subsidiaries. Lucid is subject to certain customary affirmative and negative covenants regarding the rank of the note, along with the incurrence of further indebtedness, the existence of liens, the repayment of indebtedness and the making of investments, the payment of cash in respect of dividends, distributions or redemptions, the transfer of assets, the maturity of other indebtedness, and transactions with affiliates, among other customary matters. Lucid is subject to financial covenants requiring: (i) a minimum of $5.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) Lucid’s average market capitalization over the prior ten trading days, as of the last day of any fiscal quarter commencing with September 30, 2023, to not exceed 30%; and (iii) Lucid’s market capitalization to at no time be less than $30 million In the nine months ended September 30, 2023, approximately $ 92 of principal repayments along with approximately $ 48 of interest expense thereon, were settled through the issuance of 115,388 shares of common stock of Lucid, with such shares having a fair value of approximately $ 166 (with such fair value measured as the respective conversion date quoted closing price of the common stock of Lucid). The conversions resulted in a debt extinguishment loss of $ 26 in the three and nine months ended September 30, 2023. During the three and nine months ended September 30, 2023, the Company recognized debt extinguishment losses in total of approximately $ 1,764 3,032 5,123 See Note 10, Financial Instruments Fair Value Measurements

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2023
Retirement Benefits [Abstract]
Stock-Based Compensation	Note 12 — Stock-Based Compensation PAVmed Inc. 2014 Long-Term Incentive Equity Plan The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (the “PAVmed 2014 Equity Plan”) is designed to enable PAVmed to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire shares of common stock of PAVmed. The types of awards that may be granted under the PAVmed 2014 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the PAVmed compensation committee. A total of 21,052,807 1,570,086 600,854 4,700,000 Note 12 — Stock-Based Compensation PAVmed Stock Options PAVmed stock options granted under the PAVmed 2014 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options Number of Stock Options Weighted Average Exercise Price Remaining Contractual Term (Years) Intrinsic Value (2) Outstanding stock options at December 31, 2022 11,568,655 $ 2.71 7.4 $ — Granted (1) 7,455,000 $ 0.47 Exercised — $ — Forfeited (1,944,170 ) $ 1.75 Outstanding stock options at September 30, 2023 (3) 17,079,485 $ 1.85 7.5 $ — Vested and exercisable stock options at September 30, 2023 8,379,277 $ 2.89 5.9 $ — (1) Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of September 30, 2023 and December 31, 2022 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above, are inclusive of 500,854 Subsequent to September 30, 2023, on November 7, 2023, the company granted to employees 775,000 0.28 vest one-third after one year then ratably over the next eight quarters. PAVmed Restricted Stock Awards PAVmed restricted stock awards granted under the PAVmed 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Stock Awards Weighted Average Grant Date Fair Value Unvested restricted stock awards as of December 31, 2022 (1) 975,000 $ 3.05 Granted 182,927 0.39 Vested (100,000 ) 3.10 Forfeited — — Unvested restricted stock awards as of September 30, 2023 1,057,927 $ 2.58 (1) The unvested restricted stock awards presented in the table above, are inclusive of 100,000 100,000 Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (“Lucid Diagnostics 2018 Equity Plan”) is separate and apart from the PAVmed 2014 Equity Plan discussed above. The Lucid Diagnostics 2018 Equity Plan is designed to enable Lucid Diagnostics to offer employees, officers, directors, and consultants, an opportunity to acquire shares of common stock of Lucid Diagnostics. The types of awards that may be granted under the Lucid Diagnostics 2018 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the Lucid Diagnostics compensation committee. A total of 11,644,000 3,929,301 423,300 50,000 2,500,000 Note 12 — Stock-Based Compensation Lucid Diagnostics Stock Options Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options Number of Stock Options Weighted Average Exercise Price Remaining Contractual Term (Years) Intrinsic Value (2) Outstanding stock options at December 31, 2022 2,565,377 $ 3.14 8.3 $ 428 Granted (1) 2,982,500 $ 1.32 Exercised — $ — Forfeited (590,662 ) $ 2.70 Outstanding stock options at September 30, 2023 (3) 4,957,215 $ 2.10 8.6 $ 347 Vested and exercisable stock options at September 30, 2023 1,439,442 $ 2.77 7.0 $ 347 (1) Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 30, 2023 and December 31, 2022 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above, are inclusive of 423,300 Subsequent to September 30, 2023, on November 6, 2023, the company granted to employees 500,000 with a weighted average exercise price of $ 1.29 vest one-third after one year then ratably over the next eight quarters. Lucid Diagnostics Restricted Stock Awards Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Stock Awards Weighted Average Grant Date Fair Value Unvested restricted stock awards as of December 31, 2022 (1) 2,091,420 $ 11.44 Granted — — Vested (303,980 ) 11.95 Forfeited — — Unvested restricted stock awards as of September 30, 2023 1,787,440 $ 11.36 (1) The unvested restricted stock awards presented in the table above, are inclusive of 50,000 50,000 Subsequent to September 30, 2023, on November 6, 2023, 550,000 vesting one third each year for the next three years with the final vesting date on November 6, 2026 0.7 Consolidated Stock-Based Compensation Expense The consolidated stock-based compensation expense recognized by each of PAVmed and Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of revenue $ 32 $ 9 $ 86 $ 9 Sales and marketing expenses 403 643 1,302 1,859 General and administrative expenses 1,499 3,854 6,761 12,016 Research and development expenses 311 258 1,022 699 Total stock-based compensation expense $ 2,245 $ 4,764 $ 9,171 $ 14,583 Note 12 — Stock-Based Compensation Stock-Based Compensation Expense Recognized by Lucid Diagnostics As noted, the consolidated stock-based compensation expense presented above is inclusive of stock-based compensation expense recognized by Lucid Diagnostics, inclusive of each of: stock options granted under the PAVmed 2014 Equity Plan to the three physician inventors of the intellectual property underlying the CWRU License Agreement (“Physician Inventors”) (as discussed above in Note 4, Related Party Transactions Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Lucid Diagnostics 2018 Equity Plan – cost of revenue $ 16 $ 9 $ 44 $ 9 Lucid Diagnostics 2018 Equity Plan – sales and marketing 228 253 697 733 Lucid Diagnostics 2018 Equity Plan – general and administrative 721 2,990 4,069 9,504 Lucid Diagnostics 2018 Equity Plan – research and development 67 28 204 125 PAVmed 2014 Equity Plan - cost of revenue 10 — 26 — PAVmed 2014 Equity Plan - sales and marketing 106 161 359 497 PAVmed 2014 Equity Plan - general and administrative 7 78 170 224 PAVmed 2014 Equity Plan - research and development 97 52 290 159 Total stock-based compensation expense – recognized by Lucid Diagnostics $ 1,252 $ 3,571 $ 5,859 $ 11,251 Total stock-based compensation expense $ 1,252 $ 3,571 $ 5,859 $ 11,251 The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense Unrecognized Expense Weighted Average Remaining Service Period (Years) PAVmed 2014 Equity Plan Stock Options $ 4,736 2.0 Restricted Stock Awards $ 316 1.4 Lucid Diagnostics 2018 Equity Plan Stock Options $ 3,620 2.1 Restricted Stock Awards $ 633 1.0 Stock-based compensation expense recognized with respect to stock options granted under the PAVmed 2014 Equity Plan was based on a weighted average estimated fair value of such stock options of $ 0.35 1.08 Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Nine Months Ended September 30, 2023 2022 Expected term of stock options (in years) 5.7 5.8 Expected stock price volatility 88 % 86 % Risk free interest rate 3.7 % 2.9 % Expected dividend yield — % — % Note 12 — Stock-Based Compensation Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $ 0.88 1.61 Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Nine Months Ended September 30, 2023 2022 Expected term of stock options (in years) 5.6 5.8 Expected stock price volatility 75 % 72 % Risk free interest rate 3.7 % 3.2 % Expected dividend yield — % — % PAVmed Inc. Employee Stock Purchase Plan (“PAVmed ESPP”) A total of 573,229 194,240 182 218 304,001 191,698 76 140 188,846 2,000,000 112,913 250,000 Lucid Diagnostics Inc. Employee Stock Purchase Plan (“Lucid ESPP”) A total of 231,987 276 276,213 84,030 275 109 1,000,000 407,770 500,000

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Preferred Stock	Note 13 — Preferred Stock As of September 30, 2023 and December 31, 2022, there were 1,279,601 1,205,759 Series B Convertible Preferred Stock Dividends The PAVmed Inc. Series B Convertible Preferred Stock dividends are 8.0 3.00 Series B Convertible Preferred Stock Dividends Earned The Series B Convertible Preferred Stock dividends earned are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each of the respective corresponding periods presented in the accompanying unaudited condensed consolidated statement of operations, inclusive of $ 77 226 71 209 Series B Convertible Preferred Stock Dividends Declared In the nine months ended September 30, 2023, the Company’s board-of-directors declared Series B Convertible Preferred Stock dividends of an aggregate of $ 221 72 74 75 73,842 24,128 24,610 25,104 Note 13 — Preferred Stock In the nine months ended September 30, 2022, the Company’s board-of-directors declared Series B Convertible Preferred Stock dividends of an aggregate of $ 205 67 68 70 68,227 22,291 22,740 23,196 Subsequent to September 30, 2023, in October 2023, the Company’s board of directors declared a Series B Convertible Preferred Stock dividend, earned as of September 30, 2023, of $ 77 25,612 The Series B Convertible Preferred Stock dividends are recognized as a dividend payable liability only upon the dividend being declared payable by the Company’s board of directors. Accordingly, the dividends declared payable subsequent to the date of the accompanying condensed consolidated balance sheet were not recognized as a dividend payable liability as the Company’s board of directors had not declared the dividends payable as of each such date.

Common Stock and Common Stock P

Common Stock and Common Stock Purchase Warrants	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Common Stock and Common Stock Purchase Warrants	Note 14 — Common Stock and Common Stock Purchase Warrants Common Stock On December 29, 2022, the Company received a notice from the Listing Qualifications Department of Nasdaq stating that, for the prior 30 consecutive business days (through December 28, 2022), the closing bid price of the Company’s common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification letter stated that the Company would be afforded 180 calendar days (until June 27, 2023) to regain compliance. On June 28, 2023, the Company received a second notice from the Listing Qualifications Department of Nasdaq granting the Company a 180-day extension (or until December 26, 2023) to regain compliance with the minimum bid price requirement. In order to regain compliance, the closing bid price of the Company’s common stock must be at least $1 for a minimum of ten consecutive business days . During the special meeting (“Special Meeting”) of shareholders held on March 31, 2023, the shareholders approved a proposal to amend the Company’s Certificate of Incorporation, to effect, at any time prior to the one-year anniversary date of the Special Meeting, (i) a reverse split of the Company’s outstanding shares of common stock at a specific ratio, ranging from 1-for-5 to 1-for-15, to be determined by the board of directors of the Company in its sole discretion, and (ii) an associated reduction in the number of shares of common stock the Company is authorized to issue, from 250,000,000 shares to 50,000,000 shares. If the Company’s board of directors authorizes the Company to consummate the reverse stock split, the Company anticipates it will regain compliance with the Nasdaq requirements for continued listing through such transaction. As discussed above in Note 10, Financial Instruments Fair Value Measurements 1,500,000 602 Financial Instruments Fair Value Measurements During the nine months ended September 30, 2023 a total of 877,230 Stock-Based Compensation In the nine months ended September 30, 2023, 20,383,445 5,102 Debt In the nine months ended September 30, 2023, the Company sold 2,330,747 1,165 3 Common Stock Purchase Warrants As of September 30, 2023 and December 31, 2022, Series Z Warrants outstanding totaled 11,937,450 1.60 April 30, 2024 no

Noncontrolling Interest

Noncontrolling Interest	9 Months Ended
	Sep. 30, 2023
Noncontrolling Interest [Abstract]
Noncontrolling Interest	Note 15 — Noncontrolling Interest The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows: Schedule of Noncontrolling Interest of Stockholders' Equity 2023 NCI – equity – December 31, 2022 $ 20,615 Net loss attributable to NCI (11,716 ) Impact of subsidiary equity transactions (1,984 ) Lucid Diagnostics Inc. proceeds from issuance of preferred stock 13,625 Lucid Diagnostics Inc. proceeds from At-The-Market Facilities, net of deferred financing charges 284 Lucid Diagnostics Inc. issuance of common stock for settlement of APA-RDx installment and termination payment 713 Lucid Diagnostics Inc. issuance of common stock for settlement of vendor service agreement 147 Lucid Diagnostics Inc. Employee Stock Purchase Plan Purchase 551 Conversion of Lucid Diagnostics Inc. common stock for Senior Secured Convertible Debt 167 Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan 5,014 Stock-based compensation expense - Veris Health Inc. 2021 Equity Plan 15 NCI – equity – September 30, 2023 $ 27,431 The consolidated NCI presented above is with respect to the Company’s consolidated majority-owned subsidiaries as a component of consolidated total stockholders’ equity as of September 30, 2023 and December 31, 2022; and the recognition of a net loss attributable to the NCI in the unaudited condensed consolidated statement of operations for the periods beginning on the acquisition date of the respective majority-owned subsidiaries. Lucid Diagnostics As of September 30, 2023, there were 42,329,864 31,302,420 On March 7, 2023, Lucid issued 13,625 1,000 1.394 20 13.625 In November 2022, Lucid Diagnostics entered into an “at-the-market offering” for up to $ 6.5 230,068 0.3 3 No Subsequent to September 30, 2023, on October 17, 2023, Lucid issued 5,000 1.2592 5.0 Veris Health As of September 30, 2023, there were 8,000,000 80.44 19.56

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	Note 16 — Net Loss Per Share The Net loss per share - attributable to PAVmed Inc. - basic and diluted and Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows: Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Numerator Net loss - before noncontrolling interest $ (21,750 ) $ (29,932 ) $ (61,855 ) $ (78,666 ) Net loss attributable to noncontrolling interest 4,079 3,806 11,716 10,143 Net loss - as reported, attributable to PAVmed Inc. $ (17,671 ) $ (26,126 ) $ (50,139 ) $ (68,523 ) Series B Convertible Preferred Stock dividends – earned $ (77 ) $ (71 ) $ (226 ) $ (209 ) Net loss attributable to PAVmed Inc. common stockholders $ (17,748 ) $ (26,197 ) $ (50,365 ) $ (68,732 ) Denominator Weighted average common shares outstanding, basic and diluted 111,941,269 89,758,927 104,516,464 87,724,124 Net loss per share Basic and diluted Net loss - as reported, attributable to PAVmed Inc. $ (0.16 ) $ (0.29 ) $ (0.48 ) $ (0.78 ) Net loss attributable to PAVmed Inc. common stockholders $ (0.16 ) $ (0.29 ) $ (0.48 ) $ (0.78 ) The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows: The Series B Convertible Preferred Stock dividends earned as of each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company’s board of directors. Basic weighted-average number of shares of common stock outstanding for the periods ended September 30, 2023 and 2022 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows: Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share 2023 2022 September 30, 2023 2022 Stock options and restricted stock awards 18,137,412 12,586,571 Series Z Warrants 11,937,450 11,937,450 Series B Convertible Preferred Stock 1,279,601 1,182,101 Total 31,354,463 25,706,122 The total stock options and restricted stock awards are inclusive of 500,854 100,000 100,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies The Company’s significant accounting policies are as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on March 14, 2023, except as otherwise noted herein below.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of PAVmed and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), and include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority-ownership interest and has controlling financial interest in each of: Lucid Diagnostics and Veris Health, with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity (deficit), including the recognition in the unaudited condensed consolidated statement of operations of a net loss attributable to the noncontrolling interest based on the respective minority-interest equity ownership of each majority-owned subsidiary. See Note 15, Noncontrolling Interest As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2022 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Company’s unaudited condensed consolidated financial information. The consolidated results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2023 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Company’s audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K as filed with the SEC on March 14, 2023. All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts. Note 2 — Summary of Significant Accounting Policies
Use of Estimates	Use of Estimates In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.
Revenue Recognition	Revenue Recognition Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient’s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The key aspects considered by the Company include the following: Contracts Performance obligations Transaction price If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience. Allocate transaction price Practical Expedients Note 2 — Summary of Significant Accounting Policies
Fair Value Option (“FVO”) Election	Fair Value Option (“FVO”) Election Under a Securities Purchase Agreement dated March 31, 2022, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the “April 2022 Senior Convertible Note”, and a Senior Secured Convertible Note dated September 8, 2022, referred to herein as the “September 2022 Senior Convertible Note”, which are accounted under the “fair value option election” as discussed below. Under a Securities Purchase Agreement dated March 13, 2023, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the “Lucid March 2023 Senior Convertible Note”, which is accounted under the “fair value option election” as discussed below. Under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivative and Hedging Alternatively, FASB ASC Topic 825, Financial Instruments See Note 10, Financial Instruments Fair Value Measurements Debt
Reclassifications	Reclassifications Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the unaudited condensed consolidated financial statements and accompanying notes to the unaudited condensed consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The updated guidance requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets, including trade receivables. The guidance was adopted by the Company on January 1, 2023. The adoption of the ASU did not have an impact on the Company’s unaudited condensed consolidated financial statements.

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Schedule of Incurred Expenses of Minority Shareholders	Schedule of Incurred Expenses of Minority Shareholders 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of Revenue CWRU – Royalty Fees $ 42 $ 4 $ 76 $ 13 Cost of revenue $ 42 $ 4 $ 76 $ 13 General and Administrative Expense Amended CWRU – License Agreement - reimbursement of patent legal fees 343 — 732 209 Stock-based compensation expense – Physician Inventors’ restricted stock awards — 275 180 819 Research and Development Expense Fees - Physician Inventors’ consulting agreements 5 15 15 32 Sponsored research agreement — 4 — 6 Stock-based compensation expense – Physician Inventors’ stock options 52 52 157 151 Total Related Party Expenses $ 442 $ 350 $ 1,160 $ 1,230

Prepaid Expenses, Deposits, a_2

Prepaid Expenses, Deposits, and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Prepaid Expenses Deposits And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current Assets September 30, 2023 December 31, 2022 Advanced payments to service providers and suppliers $ 432 $ 599 Prepaid insurance 479 300 Deposits 4,581 3,005 EsoCheck cell collection supplies 190 59 EsoGuard mailer supplies — 52 Veris Box supplies 335 150 Total prepaid expenses, deposits and other current assets $ 6,017 $ 4,165

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases
Schedule of Future Lease Payments	The Company’s future lease payments as of September 30, 2023, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company’s unaudited condensed consolidated balance sheets are as follows: Schedule of Future Lease Payments 2023 (remainder of year) $ 485 2024 1,852 2025 835 2026 787 2027 617 Thereafter 1,319 Total lease payments $ 5,895 Less: imputed interest (978 ) Present value of lease liabilities $ 4,917
Schedule of Supplemental Cash Flow Information Related to Cash and Non-cash Activities with Leases	Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows: Schedule of Supplemental Cash Flow Information Related to Cash and Non-cash Activities with Leases 2023 2022 Nine Months Ended September 30, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,080 $ 763 Non-cash investing and financing activities Right-of-use assets obtained in exchange for new operating lease liabilities $ 2,728 $ 3,753 Weighted-average remaining lease term - operating leases (in years) 4.68 3.08 Weighted-average discount rate - operating leases 7.875 % 7.875 %

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Less Accumulated Amortization	Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets, Less Accumulated Amortization Estimated Useful Life September 30, 2023 December 31, 2022 Defensive asset 60 $ 2,105 $ 2,105 Laboratory licenses and certifications and laboratory information management software 24 3,200 3,200 Other 1 year 70 70 Total Intangible assets 5,375 5,375 Less Accumulated Amortization (3,446 ) (1,930 ) Intangible Assets, net $ 1,929 $ 3,445
Schedule of Estimated Amortization Expense for Intangible Assets	Schedule of Estimated Amortization Expense for Intangible Assets 2023 (remainder of year) $ 505 2024 688 2025 421 2026 315 Total $ 1,929

Financial Instruments Fair Va_2

Financial Instruments Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis	The fair value hierarchy table for the periods indicated is as follows: Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis Fair Value Measurement on a Recurring Basis at Reporting Date Using 1 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total September 30, 2023 Senior Secured Convertible Note - April 2022 $ — $ — $ 19,400 $ 19,400 Senior Secured Convertible Note - September 2022 — — 11,100 11,100 Lucid Senior Secured Convertible Note - March 2023 — — 14,490 14,490 Derivative liability — — 291 291 Totals $ — $ — $ 45,281 $ 45,281 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total December 31, 2022 Senior Secured Convertible Note - April 2022 $ — $ — $ 22,000 $ 22,000 Senior Secured Convertible Note - September 2022 — — 11,650 11,650 Totals $ — $ — $ 33,650 $ 33,650 1 There were no transfers between the respective Levels during the period ended September 30, 2023.
Schedule of Fair Value Assumption Used	The estimated fair value of the Lucid March 2023 Senior Convertible Note as of each of March 21, 2023 and September 30, 2023, and the estimated fair value of the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note as of September 30, 2023, were computed using a Monte Carlo simulation of the present value of its cash flows using a synthetic credit rating analysis and a required rate-of-return, using the following assumptions: Schedule of Fair Value Assumption Used April 2022 Senior Convertible Note: September 2022 Senior Convertible Note: Lucid March 2023 Senior Convertible Note: Lucid March 2023 Senior Convertible Note: Fair Value $ 19,400 $ 11,100 $ 11,900 $ 14,490 Face value principal payable $ 17,602 $ 10,043 $ 11,111 $ 11,019 Required rate of return 11.350 % 11.300 % 11.00 % 11.10 % Conversion Price $ 5.00 $ 5.00 $ 5.00 $ 5.00 Value of common stock $ 0.30 $ 0.30 $ 1.54 $ 1.17 Expected term (years) 0.51 0.94 2.00 1.47 Volatility 240.00 % 240.00 % 75.00 % 65.00 % Risk free rate 5.40 % 5.32 % 4.09 % 5.13 % Dividend yield — % — % — % — %
Derivative [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Schedule of Fair Value Assumption Used	The estimated fair value of the written protective put derivative liability, as such is discussed above, were computed using a Monte Carlo simulation to generate stock price paths (assuming geometric-Brownian motion) of the PAVmed Inc. common stock to compute the respective written protective put expected fair value, with the principal assumptions of such estimated fair value computation, for the respective measurement dates noted, as follows: Schedule of Fair Value Assumption Used As of: As of: Fair Value $ 262 $ 291 Contractual minimum effective conversion price $ 0.50 $ 0.50 Price per share $ 0.40 $ 0.30 Remaining expected term (years) 0.50 0.17 Volatility 160.00 % 240.00 % Risk free rate 5.30 % 5.40 % Dividend yield — % — %

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Summary of Outstanding Debt	The fair value and face value principal outstanding of the Senior Convertible Notes as of the dates indicated are as follows: Summary of Outstanding Debt Contractual Maturity Date Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value April 2022 Senior Convertible Note April 4, 2024 7.875 % $ 5.00 $ 17,602 $ 19,400 September 2022 Senior Convertible Note September 6, 2024 7.875 % $ 5.00 $ 10,043 $ 11,100 Lucid March 2023 Senior Convertible Note March 21, 2025 7.875 % $ 5.00 $ 11,019 $ 14,490 Balance as of September 30, 2023 $ 38,664 $ 44,990 Contractual Maturity Date Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value April 2022 Senior Convertible Note April 4, 2024 7.875 % $ 5.00 $ 21,497 $ 22,000 September 2022 Senior Convertible Note September 6, 2024 7.875 % $ 5.00 $ 11,250 $ 11,650 Balance as of December 31, 2022 $ 32,747 $ 33,650
Schedule of Changes in Fair Value of Debt	The changes in the fair value of debt during the three and nine months ended September 30, 2023 is as follows: Schedule of Changes in Fair Value of Debt April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - June 30, 2023 $ 19,530 $ 11,850 $ 11,610 $ 42,990 $ — Face value principal – issue date Fair value adjustment – issue date Installment repayments – common stock (952 ) (1,207 ) (92 ) (2,251 ) — Non-installment payments – common stock (41 ) (51 ) (49 ) (141 ) — Change in fair value 863 508 3,021 4,392 (4,392 ) Fair Value at September 30, 2023 $ 19,400 $ 11,100 $ 14,490 $ 44,990 - Other Income (Expense) - Change in fair value – three months ended September 30, 2023 $ (4,392 ) April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - December 31, 2022 $ 22,000 $ 11,650 $ — $ 33,650 $ — Fair Value, Beginning $ 22,000 $ 11,650 $ — $ 33,650 $ — Face value principal – issue date — — 11,111 11,111 — Fair value adjustment – issue date — — 789 789 (789 ) Installment repayments – common stock (3,895 ) (1,207 ) (92 ) (5,194 ) — Non-installment payments – common stock (249 ) (51 ) (49 ) (349 ) — Change in fair value 1,544 708 2,731 4,983 (4,983 ) Fair Value at September 30, 2023 $ 19,400 $ 11,100 $ 14,490 $ 44,990 Fair Value, Ending $ 19,400 $ 11,100 $ 14,490 $ 44,990 Other Income (Expense) - Change in fair value – nine months ended September 30, 2023 $ (5,772 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock-Based Compensation Expense	The consolidated stock-based compensation expense recognized by each of PAVmed and Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of revenue $ 32 $ 9 $ 86 $ 9 Sales and marketing expenses 403 643 1,302 1,859 General and administrative expenses 1,499 3,854 6,761 12,016 Research and development expenses 311 258 1,022 699 Total stock-based compensation expense $ 2,245 $ 4,764 $ 9,171 $ 14,583
Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics	Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Lucid Diagnostics 2018 Equity Plan – cost of revenue $ 16 $ 9 $ 44 $ 9 Lucid Diagnostics 2018 Equity Plan – sales and marketing 228 253 697 733 Lucid Diagnostics 2018 Equity Plan – general and administrative 721 2,990 4,069 9,504 Lucid Diagnostics 2018 Equity Plan – research and development 67 28 204 125 PAVmed 2014 Equity Plan - cost of revenue 10 — 26 — PAVmed 2014 Equity Plan - sales and marketing 106 161 359 497 PAVmed 2014 Equity Plan - general and administrative 7 78 170 224 PAVmed 2014 Equity Plan - research and development 97 52 290 159 Total stock-based compensation expense – recognized by Lucid Diagnostics $ 1,252 $ 3,571 $ 5,859 $ 11,251 Total stock-based compensation expense $ 1,252 $ 3,571 $ 5,859 $ 11,251
Schedule of Unrecognized Compensation Expense	The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense Unrecognized Expense Weighted Average Remaining Service Period (Years) PAVmed 2014 Equity Plan Stock Options $ 4,736 2.0 Restricted Stock Awards $ 316 1.4 Lucid Diagnostics 2018 Equity Plan Stock Options $ 3,620 2.1 Restricted Stock Awards $ 633 1.0
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Summarizes Information About Stock Options	PAVmed stock options granted under the PAVmed 2014 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options Number of Stock Options Weighted Average Exercise Price Remaining Contractual Term (Years) Intrinsic Value (2) Outstanding stock options at December 31, 2022 11,568,655 $ 2.71 7.4 $ — Granted (1) 7,455,000 $ 0.47 Exercised — $ — Forfeited (1,944,170 ) $ 1.75 Outstanding stock options at September 30, 2023 (3) 17,079,485 $ 1.85 7.5 $ — Vested and exercisable stock options at September 30, 2023 8,379,277 $ 2.89 5.9 $ — (1) Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of September 30, 2023 and December 31, 2022 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above, are inclusive of 500,854
Schedule of Restricted Stock Award Activity	PAVmed restricted stock awards granted under the PAVmed 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Stock Awards Weighted Average Grant Date Fair Value Unvested restricted stock awards as of December 31, 2022 (1) 975,000 $ 3.05 Granted 182,927 0.39 Vested (100,000 ) 3.10 Forfeited — — Unvested restricted stock awards as of September 30, 2023 1,057,927 $ 2.58 (1) The unvested restricted stock awards presented in the table above, are inclusive of 100,000 100,000
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Nine Months Ended September 30, 2023 2022 Expected term of stock options (in years) 5.7 5.8 Expected stock price volatility 88 % 86 % Risk free interest rate 3.7 % 2.9 % Expected dividend yield — % — %
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Summarizes Information About Stock Options	Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options Number of Stock Options Weighted Average Exercise Price Remaining Contractual Term (Years) Intrinsic Value (2) Outstanding stock options at December 31, 2022 2,565,377 $ 3.14 8.3 $ 428 Granted (1) 2,982,500 $ 1.32 Exercised — $ — Forfeited (590,662 ) $ 2.70 Outstanding stock options at September 30, 2023 (3) 4,957,215 $ 2.10 8.6 $ 347 Vested and exercisable stock options at September 30, 2023 1,439,442 $ 2.77 7.0 $ 347 (1) Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 30, 2023 and December 31, 2022 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above, are inclusive of 423,300
Schedule of Restricted Stock Award Activity	Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Stock Awards Weighted Average Grant Date Fair Value Unvested restricted stock awards as of December 31, 2022 (1) 2,091,420 $ 11.44 Granted — — Vested (303,980 ) 11.95 Forfeited — — Unvested restricted stock awards as of September 30, 2023 1,787,440 $ 11.36 (1) The unvested restricted stock awards presented in the table above, are inclusive of 50,000 50,000
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Nine Months Ended September 30, 2023 2022 Expected term of stock options (in years) 5.6 5.8 Expected stock price volatility 75 % 72 % Risk free interest rate 3.7 % 3.2 % Expected dividend yield — % — %

Noncontrolling Interest (Tables

Noncontrolling Interest (Tables)	9 Months Ended
	Sep. 30, 2023
Noncontrolling Interest [Abstract]
Schedule of Noncontrolling Interest of Stockholders' Equity	The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows: Schedule of Noncontrolling Interest of Stockholders' Equity 2023 NCI – equity – December 31, 2022 $ 20,615 Net loss attributable to NCI (11,716 ) Impact of subsidiary equity transactions (1,984 ) Lucid Diagnostics Inc. proceeds from issuance of preferred stock 13,625 Lucid Diagnostics Inc. proceeds from At-The-Market Facilities, net of deferred financing charges 284 Lucid Diagnostics Inc. issuance of common stock for settlement of APA-RDx installment and termination payment 713 Lucid Diagnostics Inc. issuance of common stock for settlement of vendor service agreement 147 Lucid Diagnostics Inc. Employee Stock Purchase Plan Purchase 551 Conversion of Lucid Diagnostics Inc. common stock for Senior Secured Convertible Debt 167 Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan 5,014 Stock-based compensation expense - Veris Health Inc. 2021 Equity Plan 15 NCI – equity – September 30, 2023 $ 27,431

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share	The Net loss per share - attributable to PAVmed Inc. - basic and diluted and Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows: Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Numerator Net loss - before noncontrolling interest $ (21,750 ) $ (29,932 ) $ (61,855 ) $ (78,666 ) Net loss attributable to noncontrolling interest 4,079 3,806 11,716 10,143 Net loss - as reported, attributable to PAVmed Inc. $ (17,671 ) $ (26,126 ) $ (50,139 ) $ (68,523 ) Series B Convertible Preferred Stock dividends – earned $ (77 ) $ (71 ) $ (226 ) $ (209 ) Net loss attributable to PAVmed Inc. common stockholders $ (17,748 ) $ (26,197 ) $ (50,365 ) $ (68,732 ) Denominator Weighted average common shares outstanding, basic and diluted 111,941,269 89,758,927 104,516,464 87,724,124 Net loss per share Basic and diluted Net loss - as reported, attributable to PAVmed Inc. $ (0.16 ) $ (0.29 ) $ (0.48 ) $ (0.78 ) Net loss attributable to PAVmed Inc. common stockholders $ (0.16 ) $ (0.29 ) $ (0.48 ) $ (0.78 )
Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share 2023 2022 September 30, 2023 2022 Stock options and restricted stock awards 18,137,412 12,586,571 Series Z Warrants 11,937,450 11,937,450 Series B Convertible Preferred Stock 1,279,601 1,182,101 Total 31,354,463 25,706,122

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenues	$ 791	$ 76	$ 1,403	$ 265
Monthly fees				100
Cost of revenue	$ 1,779	$ 1,626	$ 4,809	$ 1,996

Schedule of Incurred Expenses o

Schedule of Incurred Expenses of Minority Shareholders (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Cost of revenue	$ 1,779	$ 1,626	$ 4,809	$ 1,996
Total Related Party Expenses	442	350	1,160	1,230
General and Administrative Expense [Member]
Amended CWRU – License Agreement - reimbursement of patent legal fees	343		732	209
Stock-based compensation expense – Physician Inventors’ stock options		275	180	819
Research and Development Expense [Member]
Stock-based compensation expense – Physician Inventors’ stock options	52	52	157	151
Fees - Physician Inventors’ consulting agreements	5	15	15	32
Sponsored research agreement		4		6
CWRU Royalty Fees [Member]
Cost of revenue	$ 42	$ 4	$ 76	$ 13

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Outstanding payable	$ 820		$ 820
General and administrative expense	6,858	$ 10,374	23,916	$ 31,254
Consulting Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
General and administrative expense	$ 0	$ 8	$ 25	$ 45

Asset Purchase Agreement and _2

Asset Purchase Agreement and Management Services Agreement (Details Narrative) - Research Dx Inc [Member] - USD ($) $ in Thousands		1 Months Ended
	Feb. 25, 2022	Feb. 28, 2023
Asset Purchase Agreement [Member]
Business Acquisition [Line Items]
Purchase price consideration	$ 3,200
Intangible asset	$ 3,200
Management Services Agreement [Member]
Business Acquisition [Line Items]
Earnout payments and management fees remaining amount		$ 713
Number of shares issuance as payment		553,436

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Prepaid Expenses Deposits And Other Current Assets
Advanced payments to service providers and suppliers	$ 432	$ 599
Prepaid insurance	479	300
Deposits	4,581	3,005
EsoCheck cell collection supplies	190	59
EsoGuard mailer supplies		52
Veris Box supplies	335	150
Total prepaid expenses, deposits and other current assets	$ 6,017	$ 4,165

Schedule of Future Lease Paymen

Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Leases
2023 (remainder of year)	$ 485
2024	1,852
2025	835
2026	787
2027	617
Thereafter	1,319
Total lease payments	5,895
Less: imputed interest	(978)
Present value of lease liabilities	$ 4,917	$ 2,987

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information Related to Cash and Non-cash Activities with Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Leases
Operating cash flows from operating leases	$ 1,080	$ 763
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 2,728	$ 3,753
Weighted-average remaining lease term - operating leases (in years)	4 years 8 months 4 days	3 years 29 days
Weighted-average discount rate - operating leases	7.875%	7.875%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	1 Months Ended
	Sep. 30, 2022	Sep. 30, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease, right-of-use assets		$ 4,663	$ 3,037
Operating lease obligations		4,917	2,987
Operating lease, liability, current		1,574	1,141
Operating lease liability noncurrent		$ 3,343	$ 1,846
Payments for rent	$ 3,200
Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lessee operating lease description	The lease agreement term is from the September 15, 2022 execution date to the date which is seven years and eight months from the lease commencement date, with the rent abated for the first eight months of the lease term

Schedule of Intangible Assets,

Schedule of Intangible Assets, Less Accumulated Amortization (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Impairment Effects on Earnings Per Share [Line Items]
Total Intangible assets	$ 5,375	$ 5,375
Less Accumulated Amortization	(3,446)	(1,930)
Total Intangible Assets, net	$ 1,929	$ 3,445
Defensive Asset [Member]
Impairment Effects on Earnings Per Share [Line Items]
Finite lived intangible asset, useful life	60 months	60 months
Total Intangible assets	$ 2,105	$ 2,105
Laboratory Information Management Software [Member]
Impairment Effects on Earnings Per Share [Line Items]
Finite lived intangible asset, useful life	24 months	24 months
Total Intangible assets	$ 3,200	$ 3,200
Other Infinite Lived Intangible Asset [Member]
Impairment Effects on Earnings Per Share [Line Items]
Finite lived intangible asset, useful life	1 year	1 year
Total Intangible assets	$ 70	$ 70

Schedule of Estimated Amortizat

Schedule of Estimated Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2023 (remainder of year)	$ 505
2024	688
2025	421
2026	315
Total	$ 1,929	$ 3,445

Intangible Assets, net (Details

Intangible Assets, net (Details Narrative) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Oct. 05, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Impairment Effects on Earnings Per Share [Line Items]
Amortization of intangible assets		$ 505	$ 505	$ 1,516	$ 1,278
Defensive Technology [Member] | Cap Nostics LLC [Member]
Impairment Effects on Earnings Per Share [Line Items]
Assets acquisition consideration transferred	$ 2,100
Useful life	60 months

Schedule of Financial Liabiliti

Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands		Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	$ 45,281	$ 33,650
Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	291
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	45,281	33,650
Fair Value, Inputs, Level 3 [Member] | Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	291
April 2022 Senior Secured Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	19,400	22,000
April 2022 Senior Secured Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability				[1]
April 2022 Senior Secured Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
April 2022 Senior Secured Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	19,400	22,000
September 2022 Senior Secured Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	11,100	11,650
September 2022 Senior Secured Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
September 2022 Senior Secured Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
September 2022 Senior Secured Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	11,100	$ 11,650
March 2023 Lucid Senior Secured Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	14,490
March 2023 Lucid Senior Secured Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
March 2023 Lucid Senior Secured Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
March 2023 Lucid Senior Secured Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	$ 14,490
[1]There were no transfers between the respective Levels during the period ended September 30, 2023.

Schedule of Fair Value Assumpti

Schedule of Fair Value Assumption Used (Details) $ in Thousands			9 Months Ended
	May 31, 2023 USD ($)	Mar. 21, 2023 USD ($)	Sep. 30, 2023 USD ($)	Sep. 20, 2023 USD ($)	Mar. 13, 2023 USD ($)	Dec. 31, 2022 USD ($)	Sep. 08, 2022 USD ($)	Apr. 04, 2022 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument fair value			$ 44,990			$ 33,650
Face value principal payable			38,664			32,747
Derivative liability fair value	$ 262		$ 291
Measurement Input, Conversion Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input	0.50		0.50
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input	0.40		0.30
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input, term	6 months		2 months 1 day
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input	160		240
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input	5.30		5.40
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input
April 2022 Senior Secured Convertible Note [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument fair value			$ 19,400
Face value principal payable			$ 17,602					$ 27,500
April 2022 Senior Secured Convertible Note [Member] | Measurement Input Required Rate of Return [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input			11.350
April 2022 Senior Secured Convertible Note [Member] | Measurement Input, Conversion Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input			5
April 2022 Senior Secured Convertible Note [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input			0.30
April 2022 Senior Secured Convertible Note [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years			6 months 3 days
April 2022 Senior Secured Convertible Note [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input			240
April 2022 Senior Secured Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input			5.40
April 2022 Senior Secured Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input
September 2022 Senior Convertible Note [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument fair value			$ 11,100			11,650
Face value principal payable			$ 10,043			$ 11,250	$ 11,250
September 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input			11.300
September 2022 Senior Convertible Note [Member] | Measurement Input, Conversion Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input			5
September 2022 Senior Convertible Note [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input			0.30
September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years			11 months 8 days
September 2022 Senior Convertible Note [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input			240
September 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input			5.32
September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input
Lucid March 2023 Senior Convertible Note [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument fair value		$ 11,900	$ 14,490
Face value principal payable		$ 11,111	$ 11,019	$ 11,100	$ 11,100
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		11	11.10
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Conversion Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		5	5
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		1.54	1.17
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years		2 years	1 year 5 months 19 days
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		75	65
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		4.09	5.13
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input

Financial Instruments Fair Va_3

Financial Instruments Fair Value Measurements (Details Narrative) - USD ($) $ in Thousands		1 Months Ended	9 Months Ended
	May 31, 2023	May 31, 2023	Sep. 30, 2023	Mar. 21, 2023	Dec. 31, 2022	Sep. 08, 2022	Apr. 04, 2022
Short-Term Debt [Line Items]
Face value principal payable			$ 38,664		$ 32,747
Consideration service to be rendered			749
Fair market value			1,166
Fair value measurements, description		is equal-to or greater than $750, then no further contractual consideration is required. However, if such fair market value is less than $750, then, the Company will incur an additional contractual consideration obligation in amount equal to the difference between the required minimum fair market value of $750 and the contractual formula based computed fair market value
Derivative liability, fair value	$ 262	$ 262	291
Research and Development Agreement [Member]
Short-Term Debt [Line Items]
Stock issued for services, shares	1,500,000	1,500,000
Consideration service to be rendered	$ 602	$ 750
Fair market value		$ 750
April 2022 Senior Secured Convertible Note [Member]
Short-Term Debt [Line Items]
Face value principal payable			$ 17,602				$ 27,500
September 2022 Senior Secured Convertible Note [Member]
Short-Term Debt [Line Items]
Face value principal payable						$ 11,250
March 2023 Lucid Senior Secured Convertible Note [Member]
Short-Term Debt [Line Items]
Face value principal payable				$ 11,100

Summary of Outstanding Debt (De

Summary of Outstanding Debt (Details) - USD ($) $ / shares in Units, $ in Thousands					9 Months Ended	12 Months Ended
	Sep. 21, 2023	Mar. 13, 2023	Sep. 08, 2022	Apr. 04, 2022	Sep. 30, 2023	Dec. 31, 2022	Sep. 20, 2023	Mar. 21, 2023
Short-Term Debt [Line Items]
Face Value Principal Outstanding					$ 38,664	$ 32,747
Fair Value					$ 44,990	$ 33,650
April 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Maturity Date				Apr. 04, 2024	Apr. 04, 2024	Apr. 04, 2024
Stated Interest Rate				7.875%	7.875%	7.875%
Conversion Price				$ 5	$ 5	$ 5
Face Value Principal Outstanding				$ 27,500	$ 17,602	$ 21,497
Fair Value					$ 19,400	$ 22,000
September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Maturity Date			Sep. 06, 2024		Sep. 06, 2024	Sep. 06, 2024
Stated Interest Rate			7.875%		7.875%	7.875%
Conversion Price			$ 5		$ 5	$ 5
Face Value Principal Outstanding			$ 11,250		$ 10,043	$ 11,250
Fair Value					$ 11,100	$ 11,650
Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Maturity Date	Mar. 21, 2025	Mar. 21, 2025			Mar. 21, 2025
Stated Interest Rate		7.875%			7.875%		7.875%
Conversion Price		$ 5			$ 5
Face Value Principal Outstanding		$ 11,100			$ 11,019		$ 11,100	$ 11,111
Fair Value					$ 14,490			$ 11,900

Schedule of Changes in Fair Val

Schedule of Changes in Fair Value of Debt (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Short-Term Debt [Line Items]
Fair Value, Beginning	$ 42,990	$ 33,650
Face value principal – issue date		11,111
Fair value adjustment – issue date		789
Installment repayments – common stock	(2,251)	(5,194)
Non-installment payments – common stock	(141)	(349)
Change in fair value	4,392	4,983
Fair Value, Ending	44,990	44,990
Other Income (Expense) - Change in fair value	(4,392)	(5,772)
April 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Fair Value, Beginning	19,530	22,000
Face value principal – issue date
Fair value adjustment – issue date
Installment repayments – common stock	(952)	(3,895)
Non-installment payments – common stock	(41)	(249)
Change in fair value	863	1,544
Fair Value, Ending	19,400	19,400
September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Fair Value, Beginning	11,850	11,650
Face value principal – issue date
Fair value adjustment – issue date
Installment repayments – common stock	(1,207)	(1,207)
Non-installment payments – common stock	(51)	(51)
Change in fair value	508	708
Fair Value, Ending	11,100	11,100
Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Fair Value, Beginning	11,610
Face value principal – issue date		11,111
Fair value adjustment – issue date		789
Installment repayments – common stock	(92)	(92)
Non-installment payments – common stock	(49)	(49)
Change in fair value	3,021	2,731
Fair Value, Ending	14,490	14,490
Other Income Expense [Member]
Short-Term Debt [Line Items]
Fair Value, Beginning
Face value principal – issue date
Fair value adjustment – issue date		(789)
Installment repayments – common stock
Non-installment payments – common stock
Change in fair value	(4,392)	(4,983)
Fair Value, Ending

Debt (Details Narrative)

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 21, 2023	Mar. 13, 2023	Sep. 08, 2022	Apr. 04, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Sep. 20, 2023	Mar. 21, 2023	Mar. 31, 2022
Short-Term Debt [Line Items]
Debt instrument, face amount					$ 38,664		$ 38,664		$ 32,747
Debt Instrument, Fair Value Disclosure					44,990		44,990		33,650
Loss on extinguishment of debt						$ (5,123)		$ (5,123)
Interest expense					159	525	570	1,049
Loss on extinguishment of debt						$ 5,123		$ 5,123
April 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount				$ 27,500	$ 17,602		$ 17,602		$ 21,497
Debt instrument stated percentage				7.875%	7.875%		7.875%		7.875%
Conversion price				$ 5	$ 5		$ 5		$ 5
Debt instrument maturity date				Apr. 04, 2024			Apr. 04, 2024		Apr. 04, 2024
Debt Instrument, Fair Value Disclosure					$ 19,400		$ 19,400		$ 22,000
September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount			$ 11,250		$ 10,043		$ 10,043		$ 11,250
Debt instrument stated percentage			7.875%		7.875%		7.875%		7.875%
Conversion price			$ 5		$ 5		$ 5		$ 5
Debt instrument maturity date			Sep. 06, 2024				Sep. 06, 2024		Sep. 06, 2024
Debt instrument description			The Company is subject to financial covenants requiring: (i) a minimum of $8.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Company’s average market capitalization over the prior ten trading days, to not exceed 30% (the “Debt to Market Cap Ratio Test”); and (iii) the Company’s market capitalization to at no time be less than $75 million
Debt Instrument, Fair Value Disclosure					$ 11,100		$ 11,100		$ 11,650
April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Repayments of Convertible Debt							5,102
Debt Instrument, Periodic Payment, Interest							$ 300
Common Stock, Capital Shares Reserved for Future Issuance					20,383,445		20,383,445
Loss on extinguishment of debt					$ 1,738		$ 3,006
Loss on extinguishment of debt					(1,738)		(3,006)
Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount		$ 11,100			$ 11,019		$ 11,019			$ 11,100	$ 11,111
Debt instrument stated percentage		7.875%			7.875%		7.875%			7.875%
Conversion price		$ 5			$ 5		$ 5
Debt instrument maturity date	Mar. 21, 2025	Mar. 21, 2025					Mar. 21, 2025
Debt instrument description							(i) a minimum of $5.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) Lucid’s average market capitalization over the prior ten trading days, as of the last day of any fiscal quarter commencing with September 30, 2023, to not exceed 30%; and (iii) Lucid’s market capitalization to at no time be less than $30 million
Repayments of Convertible Debt							$ 92
Debt Instrument, Periodic Payment, Interest							$ 48
Common Stock, Capital Shares Reserved for Future Issuance					115,388		115,388
Debt Instrument, Fair Value Disclosure					$ 14,490		$ 14,490				$ 11,900
Loss on extinguishment of debt					1,764		3,032
Proceeds from convertible debt		$ 9,925
Debt instrument fee amount		$ 1,186
Interest expense					148		391
Principal repayment	$ 292
Extinguishment of Debt, Gain (Loss), Net of Tax							26
Loss on extinguishment of debt					(1,764)		(3,032)
Investor [Member] | April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Debt Instrument, Fair Value Disclosure					8,408		8,408
Investor [Member] | Other Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Debt Instrument, Fair Value Disclosure					$ 166		$ 166
Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount												$ 50,000
Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member] | Initial Issuance [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount												27,500
Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member] | Additional Issuance [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount												$ 22,500

Schedule of Summarizes Informat

Schedule of Summarizes Information About Stock Options (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	11,568,655
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 2.71
Remaining Contractual Term (Years)	7 years 4 months 24 days
Intrinsic Value Outstanding, Beginning Balance | $		[1]
Number of Stock Options, Granted | shares	7,455,000	[2]
Weighted Average Exercise Price, Granted | $ / shares	$ 0.47	[2]
Number of Stock Option, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Number of Stock Option, Forfeited | shares	(1,944,170)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 1.75
Number of Stock Options Outstanding, Ending Balance | shares	17,079,485	[3]
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 1.85	[3]
Remaining Contractual Term (Years)	7 years 6 months	[3]
Intrinsic Value Outstanding, Ending Balance | $		[1],[3]
Number of Stock Options Vested and exercisable stock options | shares	8,379,277
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 2.89
Remaining Contractual Term (Years), Vested and exercisable stock options	5 years 10 months 24 days
Intrinsic Value Exercisable, Ending Balance | $		[1]
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	2,565,377
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 3.14
Remaining Contractual Term (Years)	8 years 3 months 18 days
Intrinsic Value Outstanding, Beginning Balance | $	$ 428	[4]
Number of Stock Options, Granted | shares	2,982,500	[5]
Weighted Average Exercise Price, Granted | $ / shares	$ 1.32	[5]
Number of Stock Option, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Number of Stock Option, Forfeited | shares	(590,662)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 2.70
Number of Stock Options Outstanding, Ending Balance | shares	4,957,215	[6]
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 2.10	[6]
Remaining Contractual Term (Years)	8 years 7 months 6 days	[6]
Intrinsic Value Outstanding, Ending Balance | $	$ 347	[4],[6]
Number of Stock Options Vested and exercisable stock options | shares	1,439,442
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 2.77
Remaining Contractual Term (Years), Vested and exercisable stock options	7 years
Intrinsic Value Exercisable, Ending Balance | $	$ 347	[4]
[1]The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of September 30, 2023 and December 31, 2022 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price.[2]Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.[3]The outstanding stock options presented in the table above, are inclusive of 500,854 423,300

Schedule of Summarizes Inform_2

Schedule of Summarizes Information About Stock Options (Details) (Parenthetical) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Number of stock options granted. shares	423,300	423,300
Parent Company [Member] | 2014 Equity Plan [Member]
Number of stock options granted. shares	500,854	500,854

Schedule of Restricted Stock Aw

Schedule of Restricted Stock Award Activity (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Stock Awards, Unvested restricted stock awards, Beginning balance | shares	975,000	[1]
Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Beginning balance | $ / shares	$ 3.05	[1]
Number of Restricted Stock Awards, Granted | shares	182,927
Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 0.39
Number of Restricted Stock Awards, Vested | shares	(100,000)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 3.10
Number of Restricted Stock Awards, Forfeited | shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Number of Restricted Stock Awards, Ending balance | shares	1,057,927
Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Ending balance | $ / shares	$ 2.58
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Stock Awards, Unvested restricted stock awards, Beginning balance | shares	2,091,420	[2]
Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Beginning balance | $ / shares	$ 11.44	[2]
Number of Restricted Stock Awards, Granted | shares
Weighted Average Grant Date Fair Value, Granted | $ / shares
Number of Restricted Stock Awards, Vested | shares	(303,980)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 11.95
Number of Restricted Stock Awards, Forfeited | shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Number of Restricted Stock Awards, Ending balance | shares	1,787,440
Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Ending balance | $ / shares	$ 11.36
[1]The unvested restricted stock awards presented in the table above, are inclusive of 100,000 100,000 50,000 50,000

Schedule of Restricted Stock _2

Schedule of Restricted Stock Award Activity (Details) (Parenthetical) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted restricted stock, shares		100,000
Vested restricted stock, shares	100,000
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted restricted stock, shares		50,000
Vested restricted stock, shares	50,000

Schedule of Stock-Based Compens

Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total stock-based compensation expense	$ 2,245	$ 4,764	$ 9,171	$ 14,583
Cost Of Revenue [Member]
Total stock-based compensation expense	32	9	86	9
Selling and Marketing Expense [Member]
Total stock-based compensation expense	403	643	1,302	1,859
General and Administrative Expense [Member]
Total stock-based compensation expense	1,499	3,854	6,761	12,016
Research and Development Expense [Member]
Total stock-based compensation expense	$ 311	$ 258	$ 1,022	$ 699

Schedule of Stock-Based Compe_2

Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total stock-based compensation expense	$ 2,245	$ 4,764	$ 9,171	$ 14,583
Lucid Diagnostics Inc [Member]
Total stock-based compensation expense	1,252	3,571	5,859	11,251
Cost Of Revenue [Member]
Total stock-based compensation expense	32	9	86	9
Selling and Marketing Expense [Member]
Total stock-based compensation expense	403	643	1,302	1,859
General and Administrative Expense [Member]
Total stock-based compensation expense	1,499	3,854	6,761	12,016
Research and Development Expense [Member]
Total stock-based compensation expense	311	258	1,022	699
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Cost Of Revenue [Member]
Total stock-based compensation expense	16	9	44	9
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	228	253	697	733
Lucid Diagnostics Inc 2018 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	721	2,990	4,069	9,504
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	67	28	204	125
PAVmed Inc 2014 Equity Plan [Member] | Cost Of Revenue [Member]
Total stock-based compensation expense	10		26
PAVmed Inc 2014 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	106	161	359	497
PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	7	78	170	224
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	$ 97	$ 52	$ 290	$ 159

Schedule of Unrecognized Compen

Schedule of Unrecognized Compensation Expense (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Equity Option [Member] | PAVmed Inc 2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 4,736
Weighted Average Remaining Service Period	2 years
Equity Option [Member] | Lucid Diagnostics Inc 2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 3,620
Weighted Average Remaining Service Period	2 years 1 month 6 days
Restricted Stock [Member] | PAVmed Inc 2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 316
Weighted Average Remaining Service Period	1 year 4 months 24 days
Restricted Stock [Member] | Lucid Diagnostics Inc 2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 633
Weighted Average Remaining Service Period	1 year

Schedule of Fair Values of Stoc

Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 8 months 12 days	5 years 9 months 18 days
Expected stock price volatility	88%	86%
Risk free interest rate	3.70%	2.90%
Expected dividend yield
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 7 months 6 days	5 years 9 months 18 days
Expected stock price volatility	75%	72%
Risk free interest rate	3.70%	3.20%
Expected dividend yield

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	3 Months Ended		9 Months Ended			12 Months Ended
		Nov. 07, 2023	Nov. 06, 2023	Jan. 31, 2023	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2023		Sep. 30, 2022	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from common stock							$ 1,166
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							2,000,000
Shares available for issue							112,913
Number of shares increase in available for issue				250,000
Number of common stock purchased					573,229	194,240	304,001		191,698
Proceeds from common stock					$ 182	$ 218	$ 76		$ 140
Treasury stock					188,846
Lucid Diagnostics Inc [Member] | Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							1,000,000
Shares available for issue							407,770
Number of common stock purchased					231,987		276,213		84,030
Proceeds from common stock					$ 276		$ 275		$ 109
Increase in reserve				500,000
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							21,052,807
Shares available for issue							1,570,086
Number of stock options outstanding							600,854
Number of shares increase in available for issue				4,700,000
Number of restricted stock awards granted										100,000
Weighted average fair value of stock options							$ 0.35		$ 1.08
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding							17,079,485	[1]		11,568,655
Number of stock options granted	[2]						7,455,000
Weighted average exercise price	[2]						$ 0.47
2014 Equity Plan [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options granted		775,000
Weighted average exercise price		$ 0.28
Share-based compensation arrangement by share-based payment award, description		vest one-third after one year then ratably over the next eight quarters.
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding							4,957,215	[3]		2,565,377
Number of stock options granted	[4]						2,982,500
Weighted average exercise price	[4]						$ 1.32
Weighted average fair value of stock options							$ 0.88		$ 1.61
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							11,644,000
Shares available for issue							3,929,301
Number of shares increase in available for issue				2,500,000
Number of stock options granted							423,300
Number of restricted stock awards granted, shares							50,000
Number of restricted stock awards granted										50,000
2018 Equity Plan [Member] | Subsequent Event [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options granted			500,000
Weighted average exercise price			$ 1.29
Share-based compensation arrangement by share-based payment award, description			vest one-third after one year then ratably over the next eight quarters.
Number of restricted stock awards granted			550,000
Share based compensation arrangement by share based payment award equity instruments other than options vesting description			vesting one third each year for the next three years with the final vesting date on November 6, 2026
Fair value of restricted stock granted			$ 700
[1]The outstanding stock options presented in the table above, are inclusive of 500,854 423,300

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - Series B Convertible Preferred Stock [Member] - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended						6 Months Ended		9 Months Ended
	Oct. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Class of Stock [Line Items]
Preferred stock shares outstanding		1,279,601		1,205,759						1,279,601
Dividend rate percentage										8%
Preferred stock par value per share		$ 3								$ 3
Dividends payable		$ 77			$ 71					$ 226	$ 209
Board of Directors [Member]
Class of Stock [Line Items]
Dividends payable				$ 72			$ 67			$ 221	$ 205
Dividends payable			$ 74			$ 68		$ 75	$ 70
Stock issued during period, shares, new issues										73,842	68,227
Dividends preferred stock			24,610	24,128		22,740	22,291	25,104	23,196
Board of Directors [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Dividends payable	$ 77
Stock issued during period, shares, new issues	25,612

Common Stock and Common Stock_2

Common Stock and Common Stock Purchase Warrants (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended	9 Months Ended
	May 31, 2023	Dec. 29, 2022	May 31, 2023	Mar. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity, Reverse Stock Split		the Company received a notice from the Listing Qualifications Department of Nasdaq stating that, for the prior 30 consecutive business days (through December 28, 2022), the closing bid price of the Company’s common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification letter stated that the Company would be afforded 180 calendar days (until June 27, 2023) to regain compliance. On June 28, 2023, the Company received a second notice from the Listing Qualifications Department of Nasdaq granting the Company a 180-day extension (or until December 26, 2023) to regain compliance with the minimum bid price requirement. In order to regain compliance, the closing bid price of the Company’s common stock must be at least $1 for a minimum of ten consecutive business days		the Company’s Certificate of Incorporation, to effect, at any time prior to the one-year anniversary date of the Special Meeting, (i) a reverse split of the Company’s outstanding shares of common stock at a specific ratio, ranging from 1-for-5 to 1-for-15, to be determined by the board of directors of the Company in its sole discretion, and (ii) an associated reduction in the number of shares of common stock the Company is authorized to issue, from 250,000,000 shares to 50,000,000 shares. If the Company’s board of directors authorizes the Company to consummate the reverse stock split, the Company anticipates it will regain compliance with the Nasdaq requirements for continued listing through such transaction.
Stock issued for services					$ 749
At-the-market equity facility, shares					2,330,747
At-the-market equity facility, value					$ 1,165
Series Z Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total warrants outstanding					11,937,450	11,937,450
Exercise price					$ 1.60	$ 1.60
Warrants expire date					Apr. 30, 2024	Apr. 30, 2024
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued for services, shares					1,500,000
Stock issued for services					$ 2
Payments for commissions percentage					3%
Series Z Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants exercised					0
April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Convertible common stock shares issued upon conversion					20,383,445
Debt Instrument, Convertible, If-converted Value in Excess of Principal					$ 5,102
Employee Stock Purchase Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock issued					877,230
Research and Development Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued for services, shares	1,500,000		1,500,000
Stock issued for services	$ 602		$ 750

Schedule of Noncontrolling Inte

Schedule of Noncontrolling Interest of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Noncontrolling Interest [Abstract]
NCI – equity – December 31, 2022			$ 20,615
Net loss attributable to NCI	$ (4,079)	$ (3,806)	(11,716)	$ (10,143)
Impact of subsidiary equity transactions			(1,984)
Lucid Diagnostics Inc. proceeds from issuance of preferred stock			13,625
Lucid Diagnostics Inc. proceeds from At-The-Market Facilities, net of deferred financing charges			284
Lucid Diagnostics Inc. issuance of common stock for settlement of APA-RDx installment and termination payment			713
Lucid Diagnostics Inc. issuance of common stock for settlement of vendor service agreement			147
Lucid Diagnostics Inc. Employee Stock Purchase Plan Purchase			551
Conversion of Lucid Diagnostics Inc. common stock for Senior Secured Convertible Debt	167		167
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan			5,014
Stock-based compensation expense - Veris Health Inc. 2021 Equity Plan			15
NCI – equity – September 30, 2023	$ 27,431		$ 27,431

Noncontrolling Interest (Detail

Noncontrolling Interest (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended	9 Months Ended
	Oct. 17, 2023	Mar. 07, 2023	Nov. 30, 2022	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock shares outstanding				119,701,959	119,701,959	94,510,537
Issuance of shares value					$ 1,166,000
Veris Health Inc [Member] | Unrelated Third Parties [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Investment ownership percentage				19.56%	19.56%
Veris Health Inc [Member] | Parent Company [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Investment ownership percentage				80.44%	80.44%
Series A Preferred Stock [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Sale of stock, transaction value		$ 13,625,000
Lucid Series A-1 Preferred Stock [Member] | Subsequent Event [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of shares issued	5,000
Preferred stock conversion price	$ 1.2592
Sale of stock, transaction value	$ 5,000,000
Series A Convertible Preferred Stock [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of shares issued		13,625
Issuance of shares value		$ 1,000
Preferred stock conversion price		$ 1.394
Dividend percentage		20%
Lucid Diagnostics Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock shares outstanding				42,329,864	42,329,864
Partners capital account units acquisitions					31,302,420
Sale of stock, transaction value					$ 300,000
Sale of stock, sold					230,068
Sale of stock, commission percenatge					3%
Number of shares sold through market equity facility				0
Lucid Diagnostics Inc [Member] | Maximum [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Sale of stock, transaction value			$ 6,500,000
Veris Health Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock shares outstanding				8,000,000	8,000,000

Schedule of Comparison of Basic

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Net loss - before noncontrolling interest	$ (21,750)	$ (29,932)	$ (61,855)	$ (78,666)
Net loss attributable to noncontrolling interest	4,079	3,806	11,716	10,143
Net loss - as reported, attributable to PAVmed Inc.	(17,671)	(26,126)	(50,139)	(68,523)
Series B Convertible Preferred Stock dividends – earned	(77)	(71)	(226)	(209)
Net loss attributable to PAVmed Inc. common stockholders	$ (17,748)	$ (26,197)	$ (50,365)	$ (68,732)
Weighted average common shares outstanding, basic	111,941,269	89,758,927	104,516,464	87,724,124
Weighted average common shares outstanding, diluted	111,941,269	89,758,927	104,516,464	87,724,124
Net loss - as reported, attributable to PAVmed Inc,basic	$ (0.16)	$ (0.29)	$ (0.48)	$ (0.78)
Net loss - as reported, attributable to PAVmed Inc, diluted	(0.16)	(0.29)	(0.48)	(0.78)
Net loss attributable to PAVmed Inc. common stockholders,basic	(0.16)	(0.29)	(0.48)	(0.78)
Net loss attributable to PAVmed Inc. common stockholders, diluted	$ (0.16)	$ (0.29)	$ (0.48)	$ (0.78)

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	31,354,463	25,706,122
Stock Options and Restricted Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	18,137,412	12,586,571
Series Z Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	11,937,450	11,937,450
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,279,601	1,182,101

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - 2014 Equity Plan [Member] - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued	500,854	500,854
Vested restricted stock awards	100,000
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of restricted stock awards		100,000
Vested restricted stock awards	100,000